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EDUCATIONAL OBJECTIVE: Readers will consider which patients might be good candidates for an insulin pump
Insulin pumps: 
Beyond basal-bolus
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T he advent of the insulin pump in the late 1970s was a step forward in diabetes 
treatment,1 and recent improvements make 
these devices easier to use in intensive insu-
lin management. Today, more than 400,000 
people in the United States are thought to be 
using an insulin pump.2 
See related editorial page 843
 With a pump, patients can adjust the dos-
age and discreetly give themselves boluses 
by simply pushing a button instead of giving 
themselves multiple daily injections. Also, 
pump therapy can be tailored to correct for 
hepatic glucose production in a way that in-
jections cannot. 
 This article reviews the clinical application 
of continuous subcutaneous insulin therapy—
ie, the insulin pump—and provides recommen-
dations for patient selection and management.
 ■ INDICATIONS FOR AN INSULIN PUMP
The American Association of Clinical Endo-
crinologists3 recommends considering an insu-
lin pump for patients with type 1 or 2 diabetes 
mellitus who have a clear indication: 
• Suboptimal control on basal-bolus injec-
tions, ie, not achieving glycemic goals de-
spite maximal adherence to multiple daily 
injections
• Wide and erratic glycemic excursions
• Frequent severe hypoglycemia, or hypogly-
cemia unawareness
• A marked “dawn phenomenon” (spike in 
blood glucose level early in the morning)
• Pregnancy or planning for pregnancy
• Erratic lifestyle
• Personal preference.
REVIEW
*Dr. Shubrook has disclosed consulting and research for AstraZeneca, Eli Lilly, Novo Nordisk, and 
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ABSTRACT
Insulin pumps are a major advance in diabetes manage-
ment, making insulin dosing easier and more accurate 
and providing great ﬂ exibility, safety, and efﬁ cacy for 
people who need basal-bolus insulin therapy. They are 
the preferred treatment for people with type 1 diabetes 
and many with type 2 diabetes who require insulin. This 
article reviews the basics of how insulin pumps work, 
who beneﬁ ts from a pump, and how to manage inpa-
tients and outpatients on insulin pumps.
KEY POINTS
Insulin pumps allow for more accurate insulin dosing 
than multiple daily injections, resulting in less drastic 
extremes in blood sugar.
Insulin pumps allow for more individualized basal insulin 
coverage than long-acting injectable insulin.
Both the patient and provider need a good understanding 
of insulin pump therapy for successful pump management.
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 ■ WHO IS A GOOD CANDIDATE 
FOR AN INSULIN PUMP?
Good candidates for a pump are patients with 
type 1 diabetes (and some with type 2) who are 
well versed in taking multiple daily injections, 
are already checking their glucose four or more 
times daily, “counting carbs” (estimating or, 
preferably, measuring how much carbohydrate 
they are eating, and limiting their intake ac-
cordingly), and demonstrate the ability to ad-
just their dosing appropriately (Table 1). 
 A pump is not a shortcut to checking glu-
cose less frequently or making fewer decisions. 
However, for those who actively manage their 
diabetes, it provides more real-time fl exibility 
and some important safety features, as dis-
cussed below.
 ■ IS A PUMP BETTER THAN INJECTIONS?
Several studies have compared insulin pump 
therapy and multiple daily injections.4–7 While 
some found no difference in glucose control 
in terms of hemoglobin A1c or hypoglycemia, 
others showed improved glucose control with 
pumps in patients who had higher baseline 
hemoglobin A1c levels (> 10%).6 In this sub-
group, a pump lowered hemoglobin A1c an 
additional estimated 0.65% compared with 
multiple daily injections.6 Fructosamine levels 
also improved in pump users.6 
 Using continuous glucose monitoring 
for 3 days in a study in children with type 1 
diabetes, Schreiver et al8 found lower insulin 
requirements and less-severe glycemic excur-
sions with a pump than with multiple daily 
injections. 
 A 2013 study9 of 57 patients ages 13 to 71 
with type 2 diabetes who were struggling to 
control their blood sugar with multiple daily 
injections found that they achieved better 
control with less insulin using a pump. 
 A meta-analysis found pump therapy to be 
more effective than multiple daily injections 
for those who used it more than 1 year.10 
 ■ ADVANTAGES AND DISADVANTAGES 
OF INSULIN PUMP THERAPY
Intensive glucose control reduces microvas-
cular complications in type 1 diabetes.11–14 
The advantages of using a pump include bet-
ter adherence, more accurate dosing, greater 
lifestyle fl exibility, control of the dawn phe-
nomenon without induction of nocturnal hy-
poglycemia, and the ability to suspend or tem-
porarily reduce basal insulin to compensate for 
increased physical activity.15
 Disadvantages include the high degree of 
technical aptitude required, the need for high-
level engagement, skin reactions to tape, a 
higher risk of diabetic ketoacidosis from pump 
malfunction, infusion-site problems such as 
“tunneling” of insulin (leakage of insulin 
along the outside of the cannula and back to 
the skin surface) and clogging of the infusion 
set, and a risk of inactivation of insulin from 
exposure to heat, which can lead to ketoacido-
sis in a few hours if not addressed promptly.15 
 ■ IS IT COST-EFFECTIVE?
There is evidence that continuous subcutane-
ous insulin infusion is cost-effective, both in 
general and compared with multiple daily in-
jections for children and adults with type 1 di-
abetes mellitus. Cohen and Shaw16 found that 
life expectancy and quality-adjusted life-years 
increased in pump users, although the price 
per life-year gained varied greatly depending 
on the model used. 
 And this therapy is expensive. Most pumps 
cost more than $6,000, and supplies cost about 
$300 per month. Most insurance providers 
cover this therapy for patients with type 1 dia-
betes (Table 2) but less often for those with 
type 2. Further, many insurance policies have 
A pump
is not a shortcut 
to checking 
glucose less 
frequently,
or to making 
fewer decisions
TABLE 1
Who is a good candidate for an insulin pump?
Patients with type 1 diabetes who:
Self-monitor blood glucose four times per day
Take injections more than three times a day
Have completed diabetes education and carbohydrate-counting training
Have evidence of autoimmunity (positive for islet-cell antibodies 
  or glutamic acid decarboxylase antibodies)
Have low C-peptide with normal to high glucose levels
Patients with gestational diabetes who:
Self-monitor blood glucose and are on multiple daily injections
Patients with type 2 diabetes who:
Meet the same multiple-daily injection and self-monitoring requirements 
  as for type 1 diabetes
Have evidence of beta-cell failure with low C-peptide
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copayments, and patients may fi nd a 20% co-
payment a signifi cant fi nancial burden. Physi-
cians need to obtain preapproval for insulin 
pumps from the insurance company. Typically, 
prescriptions for supplies are written annually. 
Despite these signifi cant costs, most patients 
with type 1 diabetes who use an insulin pump 
fi nd that the benefi ts of improved control and 
greater independence justify the cost. 
 An annual review of currently available 
insulin pumps and other diabetes-related 
equipment is published in Diabetes Forecast.17
 ■ PATIENT PERSPECTIVE 
ON INSULIN PUMP USE
Many patients who use a pump fi nd that it 
gives them greater fl exibility to adjust to day-
to-day changes in schedules and routines. 
For example, consuming an extra serving at 
a meal could necessitate another injection 
for a patient on multiple daily injections, but 
a pump user would need only to push a few 
buttons. With cell phone apps available to 
control some pumps, many people fi nd that 
an insulin pump is more discreet and easier 
to manage than carrying around injection 
supplies. Further, the complex calculations of 
carbohydrate ratios and correction factors are 
easier and more accurate with a pump.
 In an open-label randomized study,18 29 of 
41 patients with type 1 diabetes said they pre-
ferred a pump to multiple daily injections.
 Conversely, some people do not want a 
pump because it is attached all the time and 
identifi es them to others as having an illness. 
Other patients do not trust a machine and 
want control in their own hands. (Actually, 
machines typically are much more reliable 
and less mistake-prone than humans.)
 ■ HOW DOES A PUMP WORK COMPARED 
WITH MULTIPLE DAILY INJECTIONS?
Patients taking multiple daily injections must 
use two types of insulin: a long-acting one 
that reaches a steady level in the blood with-
out a peak and lasts from 12 to 24 hours, and 
a rapid-acting one taken with meals, usually 
having a peak of action and an effect last-
ing 3 to 5 hours. The idea is to approximate 
normal insulin patterns, with a basal level in 
the background and peaks (boluses) of insulin 
with carbohydrate intake.
 Insulin pumps use only one kind of insulin—
a rapid-acting one, ie, lispro, aspart, or glulisine. 
They preserve the basal-bolus concept, but with 
many refi nements (discussed below).15 
 Most pumps are attached to the patient by 
plastic tubing that connects the reservoir to 
a subcutaneous cannula or steel needle. How-
ever, some pumps have a reservoir directly at-
tached to a subcutaneous cannula without the 
tubing. This type of pump is controlled with a 
remote device.
 The infusion set (cannula or needle and 
tubing) and the site should be changed every 
third day to minimize the risk of infection and 
abnormal delivery due to protein buildup on 
the cannula os, epithelial healing, and irrita-
tion around the site. Failure to do so often re-
sults in higher blood glucose concentrations.19
 The patient and healthcare team work to-
TABLE 2
Centers for Medicare and Medicaid Services 
reimbursement requirements for insulin pumps
The patient has completed a comprehensive diabetes education
program and has been receiving multiple daily injections of insulin 
with frequent self-adjustments for at least 6 months before pump 
initiation.
The patient has documented self-monitoring of blood glucose
frequency an average of at least four times per day during the
previous 2 months. 
The patient must also meet at least one of the following criteria:
• Hemoglobin A1c > 7.0%
• History of recurrent hypoglycemia
• Wide ﬂ uctuations in blood glucose before mealtime
• Dawn phenomenon with fasting plasma glucose frequently 
   > 200 mg/dL, or a history of severe glycemic excursions
• Patient on pump therapy before enrollment and has documented 
   self-monitoring of blood glucose an average of at least four times 
   per day during the month before enrollment.
• Fasting C-peptide ≤ 110% of the lower limit of normal or ≤ 200% 
   of the lower limit of normal if creatinine clearance is ≤ 50 mL/min 
   with concurrent fasting plasma glucose ≤ 225 mg/dL
• Beta-cell autoantibody-positive (islet-cell antibodies or glutamic acid
   decarboxylase antibodies)
Centers for Medicare & Medicaid Services. https://www.cms.gov/manuals/iom/list.asp.
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gether to calculate the patient’s daily insulin 
needs, and the pump is programmed based on 
the patient’s requirements, lifestyle, and sensi-
tivity to insulin. Once the pump is started, the 
patient operates it to deliver the insulin dose 
according to carbohydrate intake and blood 
glucose level.
 ■ PUMP SETTINGS
Basal rate
The basal rate is programmed by the physician 
and is intended to mimic physiologic insulin 
release. The pump can be set to a number of 
basal rates within any 24-hour period. This 
provides more physiologic matching of insulin 
delivery to hourly insulin needs based on the 
patient’s daily schedule. 
 If the patient has been taking multiple 
daily injections, the hourly basal rate can be 
calculated by dividing the daily basal dose by 
24. However, lower rates are usually used after 
midnight, and rates are increased early in the 
morning to counteract the dawn phenomenon. 
 The rates can also be adjusted temporar-
ily (for up to 24 hours), with a feature called 
the temporary basal rate. People tend to have 
higher blood glucose levels when they have a 
respiratory illness, are under signifi cant stress, 
or are menstruating. Thus, a person with infl u-
enza could increase the basal rate by 25%, or 
a student could run a temporary basal rate of 
150% for 4 hours before taking a fi nal exam. 
 Conversely, exercising increases insulin’s 
effectiveness at the muscle level, and insulin 
requirements drop. To counteract this, one 
would temporarily decrease the basal rate in 
the pump before exercising. 
Many factors affect the bolus dose
A bolus of insulin is given for meals and to 
correct hyperglycemia, as with multiple daily 
injections. A pump calculates the bolus based 
on the carbohydrate ratio, correction factor, 
or both. These ratios are programmed into the 
pump by the physician. A benefi t of the insu-
lin pump is that the patient just has to input 
the amount of carbohydrates to be eaten or re-
cord a blood glucose level and the pump will 
calculate the bolus dose of insulin to be given. 
 The carbohydrate ratio is the amount of 
insulin that should be taken per amount of 
carbohydrate. A typical ratio is 1:15, meaning 
that the patient should take 1 unit of insulin 
for every 15 g of carbohydrates to be eaten. 
This varies by patient depending on insulin 
sensitivity.
 The correction factor describes how much 
the glucose level is expected to drop per unit 
of insulin given. For example, if the target 
glucose level is 100 mg/dL and the correction 
factor is 25, then the patient will get 1 unit of 
correction of insulin if his or her glucose level 
is 125 mg/dL, 2 units if it is 150 mg/dL, and so 
on. A pump can dispense fractions of a unit.
 The target glucose level or range is set by 
the physician and patient and is one of the 
factors the pump uses in calculating a bolus 
dose. Insulin pumps allow for multiple target 
glucose levels. Commonly, to minimize the 
risk of hypoglycemia, a higher (less strict) tar-
get is set for bedtime and overnight than for 
daytime.
 Active insulin time defi nes how soon the 
patient can take another bolus. 
 Often, people eat more than they thought 
they would. They may also fi nd that the glu-
cose level did not increase or decrease as much 
as expected. Many patients who actively man-
age their glucose take additional boluses of 
insulin after a meal if their glucose is higher 
than they thought it would be. A patient 
taking injections cannot know how much of 
the insulin from the before-meal bolus is still 
working and has to guess.
 Insulin pumps use a logarithmic formula 
to calculate this and prevent the user from 
“stacking” insulin boluses and lowering the 
glucose level too much. For example, if the 
active insulin time is 4 hours and the patient 
took a bolus for lunch at noon, he or she would 
be unable to take a full insulin correction dose 
until 4:00 pm. The patient can override this 
feature. Although the active insulin time var-
ies from patient to patient, it  is rarely more 
than 4 hours. 
Additional safety features
Suspend. When a person who is taking insulin 
injections starts to experience hypoglycemia, 
he or she has one option—to eat something 
to treat the low blood glucose. The insulin 
injection has already been taken and cannot 
be reversed. However, with an insulin pump 
the patient can fi rst suspend the pump so that 
Most insulin 
pumps cost
more than 
$6,000,
plus about 
$300 per month 
for supplies
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no additional insulin is infused until it is safe 
again, and then eat to treat the low sugar lev-
el. This allows the patient to eat less, prevent 
overtreating, and, hopefully, prevent rebound 
hyperglycemia.
 Reverse correction. When patients take 
insulin for an upcoming meal, they estimate 
the amount needed for the carbohydrates that 
they are about to eat as well as how much 
correction is needed. If their glucose level is 
below the target range, they may or may not 
subtract insulin from the dose to achieve the 
glucose target. The pump does this automati-
cally, resulting in a lower dose of insulin for 
that bolus. This allows the patient to take a 
bolus for a meal even if he or she is below the 
target, and thus prevent hyperglycemia.
 ■ CAN INSULIN PUMPS BE USED 
IN THE HOSPITAL?
Patients can keep using their insulin pump in 
the hospital under the right conditions. 
 Inpatient hypoglycemia increases the 
risk of death, and although not all patients 
require tight glycemic control, there is still 
benefi t in avoiding extremes in blood sugar 
levels,20 including at night.20–22 Insulin pump 
therapy, when used in the hospital, results in 
fewer episodes of severe hyperglycemia (glu-
cose levels > 300 mg/dL) and hypoglycemia 
(levels < 40 mg/dL) than multiple daily injec-
tions.22 Moreover, most pump users feel more 
comfortable when they can manage their own 
therapy. Using the pump in the hospital has 
the additional benefi t that patients can treat 
themselves before and after meals easily with 
less staff time and effort.
 Bailon et al23 retrospectively studied 35 
patients with insulin pumps in 50 hospital-
izations. More than half of the patients were 
allowed to continue using their pump in the 
hospital. Reasons for discontinuing the pump 
included lack of access to supplies, unfamil-
iarity with the pump, attempted suicide, mal-
functioning hardware, diabetic ketoacidosis, 
and altered mental status. Patients using their 
pump had fewer episodes of hypoglycemia 
(glucose levels < 70 mg/dL) than patients who 
removed their pump. In patients who contin-
ued using the pump throughout their hospital-
ization, no adverse events (eg, site infection or 
mechanical failure) were noted. 
 Leonhardi et al24 reviewed 25 hospital ad-
missions, and the outcomes were similar to 
those reported by Bailon et al,23 with no ad-
verse outcomes related to the pumps. 
When using an insulin pump in the hospital
When a physician wants a patient to continue 
using an insulin pump in the hospital, a num-
ber of things must happen. The nursing staff 
must be informed that the patient is wearing 
a pump and can self-administer insulin. Most 
facilities will still follow routine protocols for 
checking blood glucose but will document 
that the patient is administering his or her 
own insulin. The patient must be well enough 
to manage the pump. If the infusion site needs 
to be changed, the patient would be expected 
to do so with his or her own supplies. 
Imaging and insulin pumps
Advice differs on what to do if a patient with 
an insulin pump needs to undergo radio-
graphic imaging. For example, the University 
of Wisconsin radiology department says it is 
safe to keep an insulin pump in place if the 
x-ray beam will be on for less than 3 seconds 
at a time and if the device is covered by a lead 
apron.25 However, radiation can induce elec-
trical currents in the circuitry, which can al-
ter the function of the pump. For this reason, 
some manufacturers recommend removing 
the device before the patient enters any room 
in which radiation or magnetic resonance im-
aging will be used.26–31
Insulin pumps and surgery
Insulin pumps have been used in the periop-
erative and intraoperative periods, with posi-
tive outcomes.32 An analysis of 20 patients on 
pumps undergoing a total of 23 surgeries (most-
ly orthopedic procedures) found that 13 of the 
20 patients wore their pump during surgery. No 
adverse events were noted in any of these cases, 
although the sample size was small.33 
 Corney et al34 retrospectively compared 
insulin pumps with alternative methods of 
perioperative glucose management. Multiple 
surgical specialties were included. No signifi -
cant difference in mean blood glucose lev-
els was found between those who continued 
to use their pump and those who used other 
methods. In those who continued to use their 
Insulin pumps
preserve 
the basal-bolus
concept, 
but with 
refi nements
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The infusion 
set and the site 
should be 
changed 
every 3 days
pump, there were no episodes of intraopera-
tive technical diffi culties related to the pump. 
 Any patient who may be undergoing a pro-
cedure or surgery must let the surgeon and an-
esthesiologist know that he or she has a pump. If 
the infusion site is too close to the site of the 
surgery or procedure, it must be moved.
 Concerns during surgery include catheter 
or site disconnection or loss, crystallization 
within the tubing (a potential problem not 
limited to surgery), and pump malfunction. 
If the procedure involves imaging, the pump 
should probably be disconnected or covered by 
lead shielding as directed in the pump manu-
facturer’s manual. The surgeon and anesthesi-
ologist must decide whether to continue use of 
a pump during a surgical procedure. However, 
the study by Corney et al34 shows it is possible. 
 Most offi ce-based procedures can be done 
with the insulin pump in place, as the patient 
is not under general anesthesia and so can ad-
just the insulin regimen as needed.
 Abdelmalak et al,35 in a comprehensive 
review of insulin pump use in noncardiac sur-
gery, commented that the type of surgery may 
play a role in determining the best approach 
to perioperative glucose management. Major 
surgery causes a large infl ammatory response 
that makes it diffi cult to control blood sugar, 
especially when steroids or beta agonists are 
given, whereas minor surgery does not affect 
blood glucose nearly as much. The authors of-
fered recommendations on pump use during 
various surgical procedures depending on the 
length of the procedure:
• If surgery is anticipated to last less than 1 
hour, then keep the insulin pump on, and 
have the patient manage corrections pre-
operatively and postoperatively. 
• For surgery of intermediate length (1–3 
hours), have the patient take a bolus of 1 
hour’s worth of insulin (based on the basal 
rate for that time period) before the proce-
dure, then remove the insulin pump. Do 
this only if blood sugar is normal or close 
to normal. If the patient is severely hyper-
glycemic, remove the insulin pump and 
start an intravenous insulin infusion. 
• If the procedure will take more than 3 
hours, remove the pump and start an in-
sulin infusion regardless of the blood sugar 
level.35
 ■ AIR TRAVEL AND INSULIN PUMPS
Insulin pumps can be easy to manage during 
airline travel if the user is prepared (Table 3).
 First, it is important to have a letter from 
the treating physician stating that the pump 
is a necessary medical device. All supplies 
should be carried on and in a separate bag for 
easy inspection. The more forthcoming the 
user is at the security checkpoint, the easier 
the process.
 According to the Transportation Security 
Administration, insulin pump users can keep 
their pump on during screening, and the metal 
detectors and full-body scanners will not harm 
the device.36 
 However, manufacturer recommendations 
differ. Medtronic recommends that patients 
not expose their insulin pump to x-rays, and 
that instead of going through a full-body scan-
ner the patient should request a pat-down.37 
Animas recommends the same.38 OmniPod 
states that their system can be worn through 
airport imaging, making it the only approved 
continuous insulin delivery system that can be 
taken through airport imaging.39
 Another potential problem is the change 
in atmospheric pressure during takeoff and 
landing. Bubbles can form in the insulin res-
ervoir as air pressure decreases with ascent, 
thereby displacing insulin from the pump to 
the patient. The opposite happens during de-
scent. King et al40 corroborated this phenom-
enon with Animas and Medtronic pumps. 
Asante recommends removing their pump 
tubing during takeoff and landing.30 
 ■ IF PROBLEMS ARISE 
Like any machine, an insulin pump can fail. 
Most failures result in lack of insulin delivery—
the patient does not get excess insulin from 
insulin pump failure. Excess insulin delivery 
is most often due to operator error. All insulin 
is either preprogrammed (basal by provider or 
patient) or must be confi rmed by the patient 
at the time of delivery (meal or correction bo-
luses). 
 Pump manufacturers have 24-hour support 
programs and hotlines, with experts who will ei-
ther walk the patient through the problem or send 
a replacement pump—often within 24 hours.
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 ■ EVOLVING TECHNOLOGY
Pump technology is evolving quickly. On the 
way are “smart” pumps that interact with other 
systems, smaller pumps with advanced touch-
screen features, and patch pumps that do not 
have tubing but operate similarly to pumps 
with tubing (ie, a cannula is still required for 
insulin delivery). 
 Some insulin pumps can be linked to an 
external glucose sensor. These systems provide 
a great amount of information to the patient 
and provider. Often, there is increased aware-
ness of fl uctuations in glucose, allowing earlier 
intervention to prevent high and low glucose 
excursions. Sensor-augmented pumps may 
further improve safety by suspending infusion 
during hypoglycemia.41,42 
 Researchers continue to strive for closed-
loop systems that would allow the pump to 
automatically respond to circulating glucose 
and thus provide truly physiologic control.43 
A recent study showed the effectiveness of the 
outpatient use of a bihormonal (insulin and 
glucagon) “bionic pancreas,” which provided 
improved glucose control and similar or less 
hypoglycemia in adults and adolescents who 
had been using a traditional insulin pump.44 ■
TABLE 3
Recommendations for patients
with an insulin pump who plan air travel
• Bring a note from your physician stating you have diabetes mellitus 
and are carrying insulin supplies.
• Always bring extra supplies (pump supplies, syringes, test strips, 
lancets, and an extra insulin bottle). Once opened, a bottle of insulin 
can be kept at room temperature for 28 to 42 days. Those that are 
unopened should be refrigerated. 
• Notify the Transportation Security Administration (TSA) staff that 
you wear an insulin pump and have diabetic supplies before send-
ing your belongings through the x-ray machine. If you carry a pump 
with tubing, you can detach the device and send it through the x-ray 
machine. TSA staff will swab your hands after you touch the pump to 
test for explosive material, which is standard procedure.
• If you are concerned about insulin dosing during takeoff and land-
ing, you can detach your pump at these times. Make sure to prime the 
tubing again before reattaching it to ensure the tubing is free of air.
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